For this purpose, Lundbeck is engaged in the research, development, production, marketing and sale of pharmaceuticals across the world. The company’s products are targeted at diseases such as depression, schizophrenia, Parkinson’s disease and Alzheimer’s disease.
Psychiatric and neurological disorders
According to the World Health Organization, WHO, more than 700 million people lives with psychiatric and neurological disorders globally.1 These are serious and life-threatening diseases that affect the quality of life of patients as well as of their relatives.
As these diseases also involve major socio-economic costs, it is imperative for society as a whole that new and innovative pharmaceuticals are developed. Over the past 50 years, new pharmaceuticals have revolutionised treatment options, but there is still a great unmet need for new and innovative therapeutics.
More information about disease areas
Research and development
Focus on R&D is the most important pillar in Lundbeck’s ambition to improve treatment for people living with psychiatric and neurological disorders. We are specialists in our area and have research facilities in Denmark and China, and more than 1,000 employees work in our R&D units. We cooperate closely with strategic partners all over the world, ensuring the best possible foundation for innovation and the development of new treatment solutions.
More information about developing drugs
Lundbeck markets a number of different pharmaceuticals for the treatment of psychiatric and neurological disorders. The most recently launched compounds include: Rexulti® (depression and schizophrenia), Brintellix® (depression) and Abilify Maintena® (schizophrenia).
Lundbeck employs approximately 5,300 people worldwide, 1,700 of whom are based in Denmark. We have employees in 55 countries, and our products are registered in more than 100 countries. We have production facilities in China, Denmark, France and Italy and research centres in Denmark and China. Lundbeck generated revenue of approximately DKK 14.6 billion in 2015.
Lundbeck’s Executive Management consists of three members, headed by Kåre Schultz, President and CEO.
More information about the management
In 2015, 27% of our revenue derived from Europe, 44% from the US and 26% from the International Markets region. Other revenue constituted 3%.
Lundbeck was founded by Hans Lundbeck as a trading company in 1915. Since then the company has evolved and grown dramatically. Today we are among the biggest Danish companies. During the past century, millions of people have been treated with our therapies. It is complex and challenging to develop improved treatments for psychiatric and neurological disorders, but we keep our focus in order to ensure a better life for people living with psychiatric and neurological disorders.
Learn more about our history
In 1999, Lundbeck’s shares were listed on the Copenhagen Stock Exchange. The Lundbeck Foundation, which annually distributes around DKK 400-500 million in grants for various types of research each year, owns about 70% of the shares in Lundbeck, while the remaining 30% are traded on the stock exchange.